CBC Accelerator Network (CBCAN)

presents

CBC Accelerator Awardees’ Presentations:
Progress to Date & Pitch for Year 2 Funding

Tuesday, December 10, 2019
4:00 - 7:00 PM

Discovery Partners Institute
200 South Wacker Drive
Fourth Floor
Chicago, IL 60606

The CBC gratefully acknowledges support from the Searle Funds at The Chicago Community Trust
4:00 PM  Participants’ Self-Introduction

4:15 PM  Introductory Remarks
Rick Morimoto
Interim Executive Director, CBC
Nancy Tyrrell
Associate Director for Translational Activities, CBC

Presentations
Presentations will be for 20 minutes; and 10 minutes for Q & A.

4:20 PM  Terry Vanden Hoek, MD (UIC)
Novel PHLPP Peptide for Asystole / PEA Resuscitation

4:55 PM  Gregory Thatcher, PhD (UIC)
Novel BET Inhibitor for Breast Cancer Combination Therapy

5:30 PM  Networking Reception
7:00 PM  Adjourn
Terry Vanden Hoek, MD (UIC)

**Novel PHLPP Peptide for Asystole / PEA Resuscitation**

Cardiac arrest affects 600,000 people annually in the United States and is a leading cause of death. No drugs exist that improve survival from this lethal disease. While cooling a few degrees improves survival, it is difficult to implement clinically during cardiopulmonary resuscitation (CPR) and when started after CPR protect against ventricular fibrillation (VF) cardiac arrest (with expected 50% survival), but not against the most lethal forms of cardiac arrest, pulseless electrical activity (PEA) and asystole (with about 10% survival). We developed a novel peptide that reproduces critical mechanisms of CPR cooling protection without physically cooling. It significantly increases survival in pigs with VF cardiac arrest. We propose to further examine the benefit of this peptide using mouse asystole and pig PEA models. We hypothesize that this peptide administered intra-venously during CPR improves neurologically intact survival and will extend protective effects of cooling to the majority of cardiac arrest patients.

Gregory Thatcher, PhD (UIC)

**Novel BET Inhibitor for Breast Cancer Combination Therapy**

Deregulation of epigenetic processes is one of the hallmarks of cancer. Bromodomain-containing proteins are key epigenetic regulators: among 61 bromodomains, the bromodomain and extraterminal (BET) family has been targeted by inhibitors in cancer clinical trials. We have designed a novel, potent, selective BET inhibitor, YF-2-23, with superiority to many inhibitors in clinical trials, when tested in breast cancer cell lines. Although YF-2-23 may have use in multiple cancers, a persuasive argument exists for pursuing combination therapy in drug-resistant ER+ breast cancer, with a novel, proprietary, orally bioavailable selective estrogen receptor degrader (SERD). We propose to obtain crucial preclinical efficacy data on the YF-2-23 combination in xenograft models of metastatic ER+ breast cancer, resistant to endocrine therapy and CDK4/6 inhibitors.
CBC Mission

The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

- Stimulate research and education that bridge institutional boundaries,
- Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
- Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
- Enhance and promote the development of the biomedical ecosystem in Chicago,
- Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

CBC Leadership

**Richard Morimoto, PhD**, Interim Executive Director, CBC
Scientific Director, Northwestern University
T: 847-491-3340 | E: r-morimoto@northwestern.edu

**Luisa DiPietro, DDS, PhD**, Scientific Director, University of Illinois at Chicago
T: 312-355-0432 | E: Ldipiet@uic.edu

**Lucy Godley, MD, PhD**, Scientific Director, The University of Chicago
T: 773-702-4140 | E: lgodley@medicine.bsd.uchicago.edu

CBC Staff

**Kimberly Corn**, Associate Director, Business Operations and Finance, Northwestern University
T: 847-467-0357 | E: k-corn@northwestern.edu

**Jola Glotzer, MD**, Communications Director, The University of Chicago
T: 773-834-5132 | E: jolaglotzer@uchicago.edu

**Corinna Kitcharoen, MBA**, Program Coordinator, University of Illinois at Chicago
T: 312-355-3683 | E: ckitch1@uic.edu

**Sheryl Sloan, MBA**, Executive Assistant, Northwestern University
T: 847-467-4983 | E: sheryl-sloan@northwestern.edu

**Karen Snapp, DDS, PhD**, Senior Associate Director, Northwestern University
T: 847-467-0633 | E: ksnapp@northwestern.edu

**Nancy Tyrrell**, Associate Director for Translational Activities, Northwestern University
T: 847-467-1094 | E: nancy.tyrrell@northwestern.edu

www.chicagobiomedicalconsortium.org